Z. Atakan

发表

Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study

M. D. Forti, R. Murray, A. David, 2019, British Journal of Psychiatry.

Managing cannabis use in people with severe mental illness: what can be done?

Z. Atakan, 2009 .

Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control

D. Collier, P. McGuire, M. Brammer, 2014, Psychological Medicine.

An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis

P. O’Reilly, M. D. Forti, R. Murray, 2017, Biological Psychiatry.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

P. McGuire, S. Surguladze, P. Allen, 2009, Archives of general psychiatry.

Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.

Chiara Nosarti, Paul Allen, Vincent Giampietro, 2009, Archives of general psychiatry.

Provision of health promotion programmes to people with serious mental illness: a mapping exercise of four South London boroughs.

K. Greenwood, K. Ismail, F. Gaughran, 2014, Journal of psychiatric and mental health nursing.

Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function

D. Collier, P. McGuire, D. Prata, 2012, Molecular Psychiatry.

Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

A. Mechelli, P. McGuire, P. Allen, 2010, The international journal of neuropsychopharmacology.

Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience

P. McGuire, M. Brammer, V. Giampietro, 2015, Neuropsychopharmacology.

Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

P. McGuire, M. Brammer, V. Giampietro, 2012, Archives of general psychiatry.

Time perception networks and cognition in schizophrenia: A review and a proposal

Z. Atakan, José Gómez, F. Ortuño, 2014, Psychiatry Research.

Cannabis abuse and vulnerability to psychosis: targeting preventive services.

P. Fusar-Poli, Z. Atakan, A. Kolliakou, 2012, Current pharmaceutical design.

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

P. Mcguire, P. Allen, D. Ståhl, 2012, Psychological Medicine.

Neuroimaging in cannabis use: a systematic review of the literature

P. McGuire, P. Allen, S. Borgwardt, 2009, Psychological Medicine.

Cannabis aﬀects people diﬀerently: inter-subject variation in the psychotogenic eﬀects of D 9 -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

P. Allen, K. Rubia, P. Fusar-Poli, 2013 .

parents say what the -- Concerns about the children of psychiatric in-patients

Z. Atakan, P. Loader, T. Craig, 2012 .

Concerns about the children of psychiatric in-patients — what the parents say

Z. Atakan, T. Craig, P. Loader, 1997 .

Cannabis, a complex plant: different compounds and different effects on individuals

Z. Atakan, 2012, Therapeutic advances in psychopharmacology.

Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature

R. Martín-Santos, Z. Atakan, A. Zuardi, 2012, Harm Reduction Journal.

P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis —implications for therapeutics

P. McGuire, P. Fusar-Poli, R. Martín-Santos, 2009, European Neuropsychopharmacology.

Cannabis and psychosis: how important is the link?

Z. Atakan, 2004, Addiction.

Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies.

P. McGuire, R. Martín-Santos, Z. Atakan, 2012, Current pharmaceutical design.

The effect of cannabis on perception of time: a critical review.

R. Martín-Santos, P. Morrison, Z. Atakan, 2012, Current pharmaceutical design.

A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT

K. Greenwood, D. Ståhl, K. Ismail, 2020, Programme Grants for Applied Research.

Tobacco smoking and nicotine dependence in first episode and established psychosis.

R. Murray, K. Greenwood, K. Murphy, 2019, Asian journal of psychiatry.

Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial

R. Murray, A. David, K. Greenwood, 2015, Psychological Medicine.

Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial

R. Murray, A. David, K. Greenwood, 2013, BMC Psychiatry.

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

P. McGuire, G. Busatto, P. Fusar-Poli, 2011, Journal of psychopharmacology.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

P. McGuire, P. Allen, S. Borgwardt, 2012, Current pharmaceutical design.

The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

R. Murray, P. Morrison, Z. Atakan, 2016, Journal of psychopharmacology.

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

R. Murray, S. Kapur, P. McGuire, 2010, Neuropsychopharmacology.

Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study

Paul Allen, Paolo Fusar-Poli, Marc L Seal, 2010, Neuropsychopharmacology.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

P. McGuire, F. Guimarães, R. Martín-Santos, 2012, Current pharmaceutical design.

ABC of mental health: Mental health emergencies

Z. Atakan, T. Davies, 1997, BMJ.

Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)

R. Murray, A. David, K. Greenwood, 2017, BMC Psychiatry.

Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition

Philip K. McGuire, Paul Allen, Katya Rubia, 2008, Biological Psychiatry.

Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC

P. McGuire, M. Brammer, V. Giampietro, 2018, Psychological Medicine.

Is cannabis neurotoxic for the healthy brain? A meta‐analytical review of structural brain alterations in non‐psychotic users

S. Borgwardt, P. Fusar-Poli, Z. Atakan, 2013, Psychiatry and clinical neurosciences.

Hyperprolactinaemia in first episode psychosis - A longitudinal assessment

R. Murray, O. Howes, K. Greenwood, 2017, Schizophrenia Research.

Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis

P. McGuire, V. Giampietro, M. Brammer, 2015, European Neuropsychopharmacology.

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Paola Dazzan, Tiago Reis Marques, Michael Lynskey, 2015, The lancet. Psychiatry.

Cannabis and anxiety: a critical review of the evidence

P. McGuire, P. Fusar-Poli, R. Martín-Santos, 2009, Human psychopharmacology.

Cannabis use by people with severe mental illness – is it important?

Z. Atakan, 2008 .

Why do patients with psychosis use cannabis and are they ready to change their use?

R. Murray, K. Ismail, Z. Atakan, 2011, International Journal of Developmental Neuroscience.

Marijuana as Medicine? The Science beyond the Controversy

Z. Atakan, Zerrin Atakan, 2001, BMJ : British Medical Journal.

Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology

R. Murray, K. Greenwood, K. Ismail, 2021, Psychological Medicine.

S0033291721003147jra 1..11

R. Murray, K. Greenwood, K. Ismail, 2021 .

Can psychiatrists predict the one-year outcome of schizophrenia?

Z. Atakan, J. Cooper, G. Cliff, 1990, Social Psychiatry and Psychiatric Epidemiology.

Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion

R. Murray, A. David, K. Greenwood, 2017, BMC Psychiatry.

Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study

Paul Allen, Paolo Fusar-Poli, Marc L Seal, 2011, Neuropsychopharmacology.

Supervision registers and the care programme approach: a practical solution

Z. Atakan, F. Holloway, D. Roy, 1995 .

Violence on psychiatric in-patient units: what can be done?

Z. Atakan, 1995 .

Effect of image analysis software on neurofunctional activation during processing of emotional human faces

P. McGuire, P. Mcguire, P. Allen, 2010, Journal of Clinical Neuroscience.

Behavioural Observation Schedule (BOS), PIRS 2nd edition A revised edition of the PIRS (WHO, Geneva, March 1978)

Z. Atakan, J. Cooper, 1989, British Journal of Psychiatry.

The Prediction of Violence in Acute Psychiatric Units

T. Wykes, M. Leese, Z. Atakan, 2003 .

Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months?

K. Greenwood, K. Ismail, D. Castle, 2015, European Psychiatry.

Predictive value of cardiometabolic biomarkers and depressive symptoms for symptom severity and quality of life in patients with psychotic disorders.

R. Murray, A. Young, K. Greenwood, 2021, Journal of affective disorders.

Sexual dysfunction and central obesity in patients with first episode psychosis

P. McGuire, K. Greenwood, D. Ståhl, 2017, European Psychiatry.

Opposite Neural Effects of the Main Psychoactive Ingredients of Cannabis- Neural Basis for Potential Therapeutic Effects of Cannabidiol

S. Borgwardt, P. Fusar-Poli, R. Martín-Santos, 2009, European psychiatry.

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

A. David, C. Pariante, J. Powell, 2015, The lancet. Psychiatry.

Neuroimaging in cannabis use: a systematic review of the literature

P. Allen, S. Borgwardt, G. Busatto, 2009, Psychological Medicine.

Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months?

Z. Atakan, Shubulade Smith, S. Bonaccorso, 2015, European Psychiatry.

Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.

P. McGuire, F. Guimarães, G. Busatto, 2014, Current pharmaceutical design.

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

P. Allen, D. Ståhl, S. Borgwardt, 2012, Psychological Medicine.

The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

P. Morrison, Z. Atakan, N. Tunstall, 2016, Journal of psychopharmacology.